122 related articles for article (PubMed ID: 25489685)
21. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
Eskazan AE; Ayer M; Kantarcioglu B; Arica D; Demirel N; Aydin D; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Br J Haematol; 2014 Oct; 167(1):139-41. PubMed ID: 24815307
[No Abstract] [Full Text] [Related]
22. Reversal of vascular leak with imatinib.
Aman J; Peters MJ; Weenink C; van Nieuw Amerongen GP; Vonk Noordegraaf A
Am J Respir Crit Care Med; 2013 Nov; 188(9):1171-3. PubMed ID: 24180451
[No Abstract] [Full Text] [Related]
23. TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model.
Ulmer A; Tabea Tauer J; Glauche I; Jung R; Suttorp M
Klin Padiatr; 2013 May; 225(3):120-6. PubMed ID: 23716272
[TBL] [Abstract][Full Text] [Related]
24. Pulmonary arterial hypertension and chronic myeloproliferative disorders.
Di Stefano F
Am J Respir Crit Care Med; 2006 Sep; 174(5):616. PubMed ID: 16931646
[No Abstract] [Full Text] [Related]
25. Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study.
Merx K; Fabarius A; Erben P; Griesshammer M; Reiter A; Hofmann WK; Hehlmann R; Hochhaus A; Lengfelder E
Ann Hematol; 2013 Jul; 92(7):907-15. PubMed ID: 23525684
[TBL] [Abstract][Full Text] [Related]
26. [Pulmonary hypertension: tailored treatment].
Semeniuk GB
Medicina (B Aires); 2007; 67(1):104. PubMed ID: 17410651
[No Abstract] [Full Text] [Related]
27. A lymphocyte-dependent mode of action for imatinib mesylate in experimental pulmonary hypertension.
Ormiston ML; Deng Y; Rundle N; Bendjelloul F; Tsoporis JN; Parker TG; Stewart DJ; Courtman DW
Am J Pathol; 2013 May; 182(5):1541-51. PubMed ID: 23518411
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs.
Arita S; Arita N; Hikasa Y
Can Vet J; 2013 Mar; 54(3):255-61. PubMed ID: 23997262
[TBL] [Abstract][Full Text] [Related]
29. Sensorineural hearing loss following imatinib (Gleevec) administration.
Lin HW; Roberts DS; Kay J; Stankovic KM
Otolaryngol Head Neck Surg; 2012 Feb; 146(2):335-7. PubMed ID: 21753034
[No Abstract] [Full Text] [Related]
30. Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
Godinas L; Guignabert C; Seferian A; Perros F; Bergot E; Sibille Y; Humbert M; Montani D
Semin Respir Crit Care Med; 2013 Oct; 34(5):714-24. PubMed ID: 24037637
[TBL] [Abstract][Full Text] [Related]
31. [Hypoprotidemia may explain imatinib intoxication in a patient with Philadelphia-positive acute lymphoblastic leukemia].
Gaïes E; Trabelsi S; Sahnoun R; Salouage I; Jebabli N; Charfi R; Lakhal M; Hdiji S; Klouz A
Therapie; 2013; 68(2):125-7. PubMed ID: 23773356
[No Abstract] [Full Text] [Related]
32. Imatinib: cardiac risks?
Prescrire Int; 2007 Apr; 16(88):72. PubMed ID: 17465036
[No Abstract] [Full Text] [Related]
33. Severe dental erosion associated with imatinib mesylate therapy.
Kyriazoglou A; Christopoulos C
Acta Oncol; 2014 Jul; 53(7):988-90. PubMed ID: 24446745
[No Abstract] [Full Text] [Related]
34. [Experience with imatinib to treat pulmonary arterial hypertension].
García Hernández FJ; Castillo Palma MJ; González León R; Garrido Rasco R; Ocaña Medina C; Sánchez Román J
Arch Bronconeumol; 2008 Dec; 44(12):689-91. PubMed ID: 19091239
[TBL] [Abstract][Full Text] [Related]
35. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
Dika E; Barisani A; Vaccari S; Fanti PA; Ismaili A; Patrizi A
J Drugs Dermatol; 2013 May; 12(5):512-3. PubMed ID: 23652942
[No Abstract] [Full Text] [Related]
36. [Pulmonary hypertension].
Kovacs G; Olschewski H
Dtsch Med Wochenschr; 2012 Oct; 137(40):2026-8. PubMed ID: 23023615
[No Abstract] [Full Text] [Related]
37. Loss of skin pigment caused by imatinib therapy.
McPartlin S; Leach M
Br J Haematol; 2005 May; 129(4):448. PubMed ID: 15877727
[No Abstract] [Full Text] [Related]
38. Peripheral neuropathy as an adverse effect of imatinib therapy.
Chakupurakal G; Etti RJ; Murray JA
J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
[No Abstract] [Full Text] [Related]
39. Reversal of vascular leak with imatinib: a role for IL-2?
Shin JI; Eisenhut M
Am J Respir Crit Care Med; 2014 Jul; 190(1):117-8. PubMed ID: 24983224
[No Abstract] [Full Text] [Related]
40. Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.
Pitsiou G; Zarogoulidis P; Petridis D; Kioumis I; Lampaki S; Organtzis J; Porpodis K; Papaiwannou A; Tsiouda T; Hohenforst-Schmidt W; Kakolyris S; Syrigos K; Huang H; Li Q; Turner JF; Zarogoulidis K
Drug Des Devel Ther; 2014; 8():1753-63. PubMed ID: 25336919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
